Bonnet F, Burty C, Lewden C, et al; Agence Nationale de Recherches sur le Sida et les Hépatites Virales EN19 Mortalité Study Group; Mortavic Study Group. Changes in cancer mortality among HIV-infected patients: The Mortalité 2005 Survey. Clin Infect Dis. 2009;48:633-639.
Centers for Disease Control and Prevention. 1993 Revised Classification System for HIV Infection and Expanded Case Definitions for AIDS among Adolescents and Adults. MMWR. 1992;41(RR-17). Accessed at www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm on July 22, 2014.
Centers for Disease Control and Prevention. HIV/AIDS: Statistics Overview. Accessed at www.cdc.gov/hiv/statistics/basics/index.html on July 21, 2014.
Cheung MC, Pantanowitz L, Dezube BJ. AIDS-related malignancies: Emerging challenges in the era of highly active antiretroviral therapy. Oncologist. 2005;10:412-426.
Clifford GM, Polesel J, Rickenbach M, et al; Swiss HIV Cohort. Cancer risk in the Swiss HIV Cohort Study: Associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97:425-432.
Diamond C, Taylor TH, Im T, Anton-Culver H. Presentation and outcomes of systemic non-Hodgkin’s lymphoma: A comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS. Leuk Lymphoma. 2006;47:1822-1829.
Diamond C, Taylor TH, Im T, et al. Highly active antiretroviral therapy is associated with improved survival among patients with AIDS-related primary central nervous system non-Hodgkin’s lymphoma. Curr HIV Res. 2006;4:375-378.
Engels EA, Pfeiffer RM, Landgren O, Moore RD. Immunologic and virologic predictors of AIDS-related non-Hodgkin lymphoma in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr. 2010;54:78-84.
Franceschi S, Lise M, Clifford GM, et al; Swiss HIV Cohort Study. Changing patterns of cancer incidence in the early- and late-HAART periods: The Swiss HIV Cohort Study. Br J Cancer. 2010;103:416-422.
Gopal S, Achenbach CJ, Yanik EL, et al. Moving forward in HIV-associated cancer. J Clin Oncol. 2014;32:876-880.
Guiguet M, Boué F, Cadranel J, et al; Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): A prospective cohort study. Lancet Oncol. 2009;10:1152-1159.
Marrazzo JM, del Rio C, Holtgrave DR, et al. HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society–USA Panel. JAMA. 2014;312:390-409.
Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:2551-2559.
Silverberg MJ, Leyden W, Warton EM, et al. HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. J Natl Cancer Inst. 2013;105:350-360.
Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS. 2007;21:1957-1963.
Skiest DJ, Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS. 2003;17:1787-1793.
Thompson MA, Aberg JA, Cahn P, Montaner JS, et al; International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304:321-333.
UNAIDS (Joint United Nations Global AIDS Programme). Global report: UNAIDS report on the global AIDS epidemic 2013. Accessed at www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/unaids_global_report_2013_en.pdf on July 23, 2014.
Last Medical Review: 07/25/2014
Last Revised: 07/25/2014